Clene Inc (CLNN) Faces Critical Dilution Risk: Shelf, ATM, and Warrant Analysis

Critical Dilution Risk for Clene Inc. (CLNN): A Micro-Cap Under Pressure

Clene Inc. (CLNN) has triggered a CRITICAL dilution risk level with an overall score of 94, driven by a perilously short cash runway, high warrant coverage, and a lack of remaining shelf or ATM capacity. The company’s financial and structural vulnerabilities demand immediate attention from investors.

#### Cash Runway: 2.8 Months of Survival

CLNN’s reported cash reserves will last just 2.8 months, a red flag for micro-cap biotech firms. With a market cap of $83.8 million, the company lacks the liquidity to fund operations through 2027 without external financing. This tight timeline increases the likelihood of urgent capital-raising measures, which could come in the form of new shelf registrations, private placements, or warrant exercises.

The absence of shelf registration capacity or ATM program availability (both at $0) means CLNN cannot rely on existing mechanisms to raise funds. This forces the company into riskier alternatives, such as private investments in public equity (PIPEs) or exercising outstanding warrants, both of which carry severe dilution risks.

#### Warrant Exposure: 81.47% Coverage and 10.4 Million Outstanding Warrants

CLNN’s 81.47% warrant coverage ratio is among the highest observed for a micro-cap, indicating that warrants could constitute a massive dilutive event if triggered. The company has 10,410,247 outstanding warrants, which, if exercised, would increase the public float by 99.1% (from 10.5 million to 20.9 million shares).

Warrant exercises are particularly dangerous for CLNN due to their below-market strike prices, which incentivize holders to cash out during price rallies. With the stock trading at a discount to its 52-week high, warrant holders may wait for a rebound before exercising, amplifying potential dilution when it occurs.

#### Filing Activity: A Form 8-K Signals Urgency

On May 5, 2026, CLNN filed a Form 8-K, typically used to disclose material events. While the filing’s specifics are not detailed in the data, the timing aligns with the company’s dwindling cash reserves. Investors should scrutinize the 8-K for clues about impending financing moves, regulatory updates, or partnership announcements.

The filing’s accession number (0001437749-26-014946) suggests it was submitted during a period of heightened operational pressure, likely to comply with SEC disclosure rules or announce a capital-raising strategy. Given CLNN’s lack of shelf/ATM capacity, the 8-K could foreshadow a new equity offering or a convertible debt issuance—both of which would further dilute shareholders.

#### Market Structure: High Float Volatility and Short Interest

CLNN’s 82.19% public float (10.5 million shares) is unusually high for a micro-cap, making it susceptible to rapid price swings. The float’s composition includes 20.44% institutional ownership, which may force large holders to liquidate positions if dilution pressures mount.

Compounding this risk is a short interest of 1.3 million shares, or 12.4% of the float. A dilution-driven sell-off could trigger a short squeeze, temporarily boosting the stock price, only to be followed by warrant exercises and further declines. This volatile cycle could destabilize CLNN’s valuation and deter new institutional investors.

#### Investor Implications: A Perfect Storm of Risks

CLNN’s situation exemplifies the "dilution death spiral" common in cash-starved biotechs:

1. Cash depletion forces equity raises.
2. Warrant exercises and new share issuances dilute existing shareholders.
3. Price declines trigger short-covering and margin calls, worsening liquidity.

Insiders own 2.18 million shares (20.8% of the float), but their alignment with retail investors remains unclear. Institutional investors, holding 20.44% of the float, may exit if dilution escalates, further pressuring the stock.

#### Conclusion: Monitor for Immediate Financing Moves

Clene Inc. is at a critical juncture, with its survival hinging on near-term capital infusions. Investors should closely track:

• New filings for shelf registrations, ATM programs, or PIPE deals.
• Warrant activity for signs of imminent exercises.
• Form 8-K updates for strategic pivots or partnership announcements.

Failure to secure funding within 2.8 months could force CLNN into a highly dilutive emergency financing round, eroding shareholder value.